Particulate medicament in an aerosol formulation with a propellant and co-propellant
AssigneeGlaxco Group Limited
InventorsAndrew Sapsford, Andrew Patrick Savage
Life of this patent
Estimating the term…
Abstract
This invention relates to aerosol formulations of use in the administration of medicaments by inhalation. In particular, the formulations comprise (a) 1,1,1,2-tetrafluoro-ethane or 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof as propellant, (b) 1,1,2,2,3-pentafluoropropane as co-propellant, and (c) particulate medicament. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the pharmaceutical aerosol formulation is also described, as well as is a canister which is suitable for delivering the pharmaceutical aerosol formulation.
Claims24
A pharmaceutical aerosol formulation comprising
- (a) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof as propellant;
- (b) 1,1,2,2,3-pentafluoropropane as co-propellant;
- and
- (c) particulate medicament;
- wherein the particulate medicament is present in an amount of 0.005-10% w/w relative to the total weight of formulation and wherein the particle size of the particulate medicament is less than 20 microns.
A canister suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapour pressure of the propellant used which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which comprises (a) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or mixture thereof as propellant, (b) 1,1,2,2,3-pentafluoropropane as co-propellant, and (c) a particulate medicament;
- wherein the particulate medicament is present in an amount of 0.005-10% w/w relative to the total weight of formulation and wherein the particle size of the particulate medicament is less than 20 microns.
Dependencies are inferred from the claim text.